William Goodman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Calcium-sensing by parathyroid glands in secondary hyperparathyroidism
    W G Goodman
    Department of Medicine, University of California at Los Angeles School of Medicine, 90095, USA
    J Clin Endocrinol Metab 83:2765-72. 1998
  2. ncbi request reprint Renal osteodystrophy for nonnephrologists
    William G Goodman
    Division of Nephrology and the Department of Medicine, David Geffen School of Medicine at UCLA, 7 155 Factor Bldg, UCLA Medical Center, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA
    J Bone Miner Metab 24:161-3. 2006
  3. ncbi request reprint Vascular calcification in end-stage renal disease
    William G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Nephrol 15:S82-5. 2002
  4. ncbi request reprint Assays for parathyroid hormone and their use in patients with end-stage renal disease
    William G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, Calif 90095, USA
    Blood Purif 21:118-23. 2003
  5. ncbi request reprint Calcium-sensing receptors
    William G Goodman
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Semin Nephrol 24:17-24. 2004
  6. ncbi request reprint Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Pediatr Nephrol 18:1206-10. 2003
  7. ncbi request reprint The evolution of assays for parathyroid hormone
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Semin Dial 18:296-301. 2005
  8. ncbi request reprint Vascular calcification in chronic kidney disease
    William G Goodman
    Division of Nephrology, UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 43:572-9. 2004
  9. ncbi request reprint Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Curr Opin Nephrol Hypertens 14:355-60. 2005
  10. ncbi request reprint Calcium and phosphorus metabolism in patients who have chronic kidney disease
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, University of California at Los Angeles Medical Center, CA 90095, USA
    Med Clin North Am 89:631-47. 2005

Research Grants

  1. DIURNAL AND PULSATILE PTH SECRETION IN RENAL FAILURE
    William Goodman; Fiscal Year: 2001
  2. Coronary calcification in hemodialysis patients
    William Goodman; Fiscal Year: 2005

Detail Information

Publications47

  1. ncbi request reprint Calcium-sensing by parathyroid glands in secondary hyperparathyroidism
    W G Goodman
    Department of Medicine, University of California at Los Angeles School of Medicine, 90095, USA
    J Clin Endocrinol Metab 83:2765-72. 1998
    ....
  2. ncbi request reprint Renal osteodystrophy for nonnephrologists
    William G Goodman
    Division of Nephrology and the Department of Medicine, David Geffen School of Medicine at UCLA, 7 155 Factor Bldg, UCLA Medical Center, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA
    J Bone Miner Metab 24:161-3. 2006
  3. ncbi request reprint Vascular calcification in end-stage renal disease
    William G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    J Nephrol 15:S82-5. 2002
    ..Studies using this non-invasive diagnostic method may provide important new information about factors that initiate the development and mediate the progression of arterial calcification in patients with ESRD...
  4. ncbi request reprint Assays for parathyroid hormone and their use in patients with end-stage renal disease
    William G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, Calif 90095, USA
    Blood Purif 21:118-23. 2003
    ..Additional work is needed to further characterize the utility of second-generation immunometric PTH assays as predictors of bone histology in patients with ESRD...
  5. ncbi request reprint Calcium-sensing receptors
    William G Goodman
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Semin Nephrol 24:17-24. 2004
    ..Other receptors capable of responding to extracellular calcium ions also have been identified, but the functional importance of these interactions remains to be determined...
  6. ncbi request reprint Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Pediatr Nephrol 18:1206-10. 2003
    ..Calcimimetic agents have considerable potential, therefore, as part of new therapeutic strategies for SHPT...
  7. ncbi request reprint The evolution of assays for parathyroid hormone
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Semin Dial 18:296-301. 2005
    ..The current review summarizes key technical developments in the evolution of PTH assays. We also discuss the diagnostic value of various methods for measuring PTH in serum or plasma for the assessment of patients with renal bone disease...
  8. ncbi request reprint Vascular calcification in chronic kidney disease
    William G Goodman
    Division of Nephrology, UCLA Medical Center, Los Angeles, CA 90095, USA
    Am J Kidney Dis 43:572-9. 2004
  9. ncbi request reprint Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Curr Opin Nephrol Hypertens 14:355-60. 2005
    ..This mechanism of action differs fundamentally from that of the vitamin D sterols, which heretofore have been the only definitive pharmacological intervention for treating secondary hyperparathyroidism...
  10. ncbi request reprint Calcium and phosphorus metabolism in patients who have chronic kidney disease
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, University of California at Los Angeles Medical Center, CA 90095, USA
    Med Clin North Am 89:631-47. 2005
    ..Strategies for clinical management are being revised, and recent recommendations differ substantially from those used previously with a renewed emphasis on safety...
  11. ncbi request reprint Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy
    William G Goodman
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Kidney Int 63:1-11. 2003
    ....
  12. ncbi request reprint Calcimimetic agents for the treatment of secondary hyperparathyroidism
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Semin Nephrol 24:460-3. 2004
    ..Unlike the vitamin D sterols, calcimimetic compounds effectively decrease plasma PTH levels without aggravating disturbances in mineral metabolism that have been associated with adverse clinical outcomes...
  13. ncbi request reprint Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition
    W G Goodman
    Departments of Medicine and Pediatrics, University of California Los Angeles School of Medicine, CA 90095, USA
    Am J Clin Nutr 71:560-8. 2000
    ..Little is known about parathyroid gland function in patients receiving total parenteral nutrition (TPN)...
  14. ncbi request reprint Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
    W G Goodman
    Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    N Engl J Med 342:1478-83. 2000
    ....
  15. ncbi request reprint A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism
    W G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles 90095, USA
    Kidney Int 58:436-45. 2000
    ..The calcimimetic agent R-568 lowers plasma parathyroid hormone (PTH) levels in hemodialysis patients with mild secondary hyperparathyroidism, but its efficacy in those with more severe secondary hyperparathyroidism has not been studied...
  16. ncbi request reprint Non-invasive assessments of cardiovascular disease in patients with renal failure
    W G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    Curr Opin Nephrol Hypertens 10:365-9. 2001
    ..The technique may provide important information about the impact of new therapeutic strategies aimed at reducing the risks of vascular calcification in those with chronic renal failure...
  17. ncbi request reprint Calcimimetic agents for the treatment of hyperparathyroidism
    W G Goodman
    Division of Nephrology, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Curr Opin Nephrol Hypertens 10:575-80. 2001
    ..Calcimimetic compounds thus have considerable potential as a new approach to the medical management of several important clinical disorders of bone and mineral metabolism...
  18. ncbi request reprint The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
    William G Goodman
    Department of Medicine, Division of Nephrology, Medical Center, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 13:1017-24. 2002
    ....
  19. ncbi request reprint Future role of calcimimetics in end-stage renal disease
    William G Goodman
    Division of Nephrology, Department of Medicine, UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Adv Ren Replace Ther 9:200-8. 2002
    ..Calcimimetics agents have considerable potential therefore as a new approach to the medical management secondary hyperparathyroidism...
  20. pmc Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients
    Vasily Belozeroff
    Department of Global Health Economics, Amgen Inc, Thousand Oaks, California, USA
    Clin J Am Soc Nephrol 4:673-9. 2009
    ..We assessed the effects of cinacalcet on AP in a secondary analysis of controlled trial data...
  21. ncbi request reprint Medical management of secondary hyperparathyroidism in chronic renal failure
    William G Goodman
    Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Nephrol Dial Transplant 18:iii2-8. 2003
    ....
  22. ncbi request reprint Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics
    William G Goodman
    Division of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Kidney Int 74:276-88. 2008
    ....
  23. ncbi request reprint First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl
    Kevin J Martin
    Division of Nephrology, Saint Louis University, St Louis, Missouri 63110, USA
    Kidney Int 68:1236-43. 2005
    ..This study compared iPTH and biPTH assays during cinacalcet treatment in subjects with secondary HPT receiving dialysis...
  24. ncbi request reprint The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients
    Glenn M Chertow
    Division of Nephrology, Moffitt Long Hospitals and UCSF Mt Zion Medical Center, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Nephrol 23:307-14. 2003
    ..Whether the specific calcium preparation (acetate vs. carbonate) might influence the likelihood of progressive calcification was debated...
  25. ncbi request reprint Cardiovascular calcification in end-stage renal disease
    Isidro B Salusky
    Department of Pediatrics, UCLA School of Medicine, A2 331, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Nephrol Dial Transplant 17:336-9. 2002
    ..Excess of calcium load contributes to the development of cardiac calcifications; therefore, alternative strategies to diminish exogenous calcium load should be considered in patients with ESRD...
  26. ncbi request reprint Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols
    Isidro B Salusky
    David Geffen School of Medicine at UCLA, Division of Nephrology, 10833 Le Conte Boulevard, Box 951752, Los Angeles, CA 90095 1752, USA
    J Am Soc Nephrol 16:2501-8. 2005
    ..Sevelamer, however, maintained serum calcium concentrations closer to the lower end of the normal physiologic range, thereby increasing the safety of treatment with active vitamin D sterols...
  27. ncbi request reprint Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview
    Glenn M Chertow
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin J Am Soc Nephrol 2:898-905. 2007
    ..However, no prospective trials have evaluated whether interventions that modify these laboratory parameters result in a reduction in adverse cardiovascular outcomes...
  28. ncbi request reprint Importance of hyperphosphataemia in the cardio-renal axis
    William G Goodman
    UCLA Medical Center, 10833 LeConte Avenue, Los Angeles, CA 90095, USA
    Nephrol Dial Transplant 19:i4-8. 2004
    ..New strategies for controlling serum phosphorus levels and for better management of mineral metabolism in general are required to address these issues in patients with ESRD...
  29. ncbi request reprint The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease
    William G Goodman
    Division of Nephrology, UCLA School of Medicine, Los Angeles, California, USA
    Semin Dial 17:209-16. 2004
    ..The consequences of inadequately controlled secondary HPT and the adverse effects of selected therapeutic interventions for the disorder on vascular calcification and cardiovascular disease in those with CKD are discussed...
  30. ncbi request reprint Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis
    Isidro B Salusky
    Division of Pediatric Nephrology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Kidney Int 63:1801-8. 2003
    ..Whether estimates of the ratio between PTH(1-84) and ntPTH(1-84) fragments are a better predictor of bone turnover remains controversial...
  31. doi request reprint Association of cinacalcet adherence and costs in patients on dialysis
    Andrew Lee
    Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Med Econ 14:798-804. 2011
    ..This study assessed the relationship between medication adherence and healthcare costs among US patients on dialysis given cinacalcet to manage secondary hyperparathyroidism...
  32. ncbi request reprint Role of the calcium-sensing receptor in parathyroid gland physiology
    Randolph A Chen
    Div of Nephrology, 7 155 Factor Bldg, UCLA Medical Ctr, 10833 Le Conte Ave, Los Angles, CA 90095, USA
    Am J Physiol Renal Physiol 286:F1005-11. 2004
    ..The current review summarizes recent developments that enhance our understanding of the CaSR and its fundamental importance in parathyroid gland physiology...
  33. ncbi request reprint Bone density measurements in pediatric patients with renal osteodystrophy
    Eleonora M Lima
    Division of Pediatric Nephrology, Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095, USA
    Pediatr Nephrol 18:554-9. 2003
    ..05. Compared with controls, in patients with high-turnover lesions, CBD was lower ( P<0.0001) and TBD higher ( P<0.0001). These findings suggest that pQCT may be an additional tool in the assessment of renal osteodystrophy...
  34. ncbi request reprint The flavors of vitamin D: tasting the molecular mechanisms
    William G Goodman
    Kidney Int 66:1286-7. 2004
  35. ncbi request reprint Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis
    William G Goodman
    Semin Dial 20:1-4. 2007
    ..These matters serve as the focus for the current commentary...
  36. ncbi request reprint Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl
    Sharon M Moe
    Indiana University Department of Medicine, 1001 West 10th Street, OPW 526, Indianapolis, IN 46202, USA
    Nephrol Dial Transplant 20:2186-93. 2005
    ..Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium-phosphorus product in haemodialysis patients...
  37. ncbi request reprint The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
    Jill S Lindberg
    Ochsner Clinical Research Center, New Orleans, Louisiana 70121, USA
    Kidney Int 63:248-54. 2003
    ..The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism...
  38. ncbi request reprint Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry
    Gabriele Lehmann
    Division of Rheumatology and Osteology, Department of Internal Medicine III, Friedrich Schiller University of Jena, Jena, Germany
    Kidney Int 68:1206-14. 2005
    ..The aim of this study was to evaluate the specific Bio-Intact PTH (1-84) Assay (BI-PTH) in patients with various types of ROD confirmed by bone biopsy...
  39. ncbi request reprint Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention
    William G Goodman
    Nephrol Dial Transplant 17:204-7. 2002
  40. ncbi request reprint Bone histology in steroid-treated children with non-azotemic nephrotic syndrome
    Michael Freundlich
    Department of Pediatrics, University of Miami, Miami, Florida, USA
    Pediatr Nephrol 19:400-7. 2004
    ..The potential consequences of these findings on adult bone mass and ultimate height deserve further studies...
  41. ncbi request reprint Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
    Geoffrey A Block
    Denver Nephrologists, Denver, USA
    N Engl J Med 350:1516-25. 2004
    ..We report the results of two identical randomized, double-blind, placebo-controlled trials evaluating the safety and effectiveness of the calcimimetic agent cinacalcet hydrochloride...
  42. ncbi request reprint Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl
    Sharon M Moe
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 67:760-71. 2005
    ....
  43. ncbi request reprint New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments
    William G Goodman
    Nephrol Dial Transplant 17:1731-6. 2002
  44. ncbi request reprint Growth hormone and the skeleton in pediatric renal allograft recipients
    Cheryl P Sanchez
    Department of Pediatrics, University of Wisconsin Medical School, 3590 MSC Pediatrics, 1300 University Avenue, Madison, WI 53706, USA
    Pediatr Nephrol 17:322-8. 2002
    ..Thus, growth hormone therapy improves linear growth and maintains bone mass, but does not favorably affect bone formation rates in stable pediatric renal allograft recipients...
  45. ncbi request reprint Dose-dependent effects of strontium on bone of chronic renal failure rats
    Iris Schrooten
    Department of Nephrology Hypertension, University of Antwerp, Belgium
    Kidney Int 63:927-35. 2003
    ..A causal role of strontium in the development of osteomalacia was established in a chronic renal failure (CRF) rat model...
  46. ncbi request reprint Medical control of secondary hyperparathyroidism: we're not there yet
    William G Goodman
    Kidney Int 65:335-6. 2004
  47. ncbi request reprint PTH(1-84)/PTH(7-84): a balance of power
    Peter A Friedman
    Univ of Pittsburgh School of Medicine, Dept of Pharmacology, E 1347 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Am J Physiol Renal Physiol 290:F975-84. 2006
    ..Despite these developments in understanding the etiology of renal failure and the availability of new assays for bioactive PTH, no adequate surrogate for bone biopsy and quantitative bone histomorphometry has been developed...

Research Grants9

  1. DIURNAL AND PULSATILE PTH SECRETION IN RENAL FAILURE
    William Goodman; Fiscal Year: 2001
    ....
  2. Coronary calcification in hemodialysis patients
    William Goodman; Fiscal Year: 2005
    ....